Abstract
Objective To investigate the level of fructosamine in different liver diseases. Methods From October 2016 to October 2017, 153 patients with liver diseases hospitalized in Tongling Municipal Hospital were selected as study group, including 58 patients with chronic hepatitis B(CHB), 35 patients with liver cirrhosis(LC), 60 patients with primary hepatocellular carcinoma(HCC). Meanwhile, 40 healthy subjects were selected as control group.The total protein(TP), albumin (ALB), cystatin C(CysC), sialic acid(SA) and fasting blood glucose(FBG) were statistically analyzed. Results The difference of fructosamine between the HCC group and the LC group, the CHB group and the control group was statistically significant[(299.1±96.9)μmmol/L, (259.3±41.5)μmmol/L, (248.7±29.5)μmmol/L, (234.9±20.2)μmmol/L](F=11.321, P 0.05). Correlation analysis showed that there was a positive correlation between fructosamine and FBG in the CHB group(r=0.655, P 0.05). Logistic stepwise regression analysis showed that in the HCC group, fructosamine(OR=1.029, 95% CI: 1.007~1.052), CysC (OR=5 454.909, 95% CI: 78.117~380 916.873) and SA(OR=1.155, 95% CI: 1.047~1.275) were independent risk factors of HCC. Conclusion It has positive correlation between fructosamine and FBG in CHB and LC patients, fructosamine may not be related to glycometabolism in HCC patients, but the data of fructosamine reflect the degree of glycosylation of HCC tumor cells. Key words: Liver diseases; Hepatitis B; Liver cirrhosis; Liver neoplasms; Fructosamine; Glycosylation; Sialic acids
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call